Protalix BioTherapeutics Reports Third Quarter 2026 Financial Results

Protalix BioTherapeutics reported net income of $4.0 million for the third quarter of 2026, an increase from $2.4 million in the same period of 2025. For the nine months ended September 30, 2026, the company recorded net income of $26.1 million and total revenues of $75.6 million, up from $43.6 million in the prior-year period. Management stated that the company expects to meet or exceed its 2026 revenue guidance of approximately $78.0 million to $83.0 million. The company ended the quarter with $48.5 million in cash and deposits, which it intends to use to continue advancing its PRX—115 program for uncontrolled gout.